ImmunoGen, Inc. (NASDAQ:IMGN) Director Daniel M. Junius sold 46,667 shares of the firm’s stock in a transaction dated Tuesday, February 13th. The shares were sold at an average price of $10.01, for a total value of $467,136.67. Following the completion of the sale, the director now directly owns 243,367 shares in the company, valued at $2,436,103.67. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.
ImmunoGen, Inc. (NASDAQ:IMGN) traded down $0.74 during trading hours on Wednesday, reaching $9.80. The company had a trading volume of 5,240,200 shares, compared to its average volume of 3,304,313. The firm has a market capitalization of $1,394.58, a price-to-earnings ratio of -9.61 and a beta of 2.50. The company has a quick ratio of 2.78, a current ratio of 2.81 and a debt-to-equity ratio of -0.03. ImmunoGen, Inc. has a fifty-two week low of $2.40 and a fifty-two week high of $10.66.
ImmunoGen (NASDAQ:IMGN) last posted its earnings results on Friday, February 9th. The biotechnology company reported ($0.10) EPS for the quarter, missing the consensus estimate of ($0.07) by ($0.03). The business had revenue of $39.40 million during the quarter, compared to analysts’ expectations of $39.62 million. The company’s revenue was up 185.5% on a year-over-year basis. During the same period in the previous year, the company earned ($0.39) EPS. sell-side analysts anticipate that ImmunoGen, Inc. will post -1.01 EPS for the current fiscal year.
Institutional investors have recently bought and sold shares of the business. Arrowstreet Capital Limited Partnership bought a new position in ImmunoGen in the second quarter valued at about $102,000. Intl Fcstone Inc. bought a new position in ImmunoGen in the second quarter valued at about $115,000. Raymond James Financial Services Advisors Inc. bought a new position in ImmunoGen in the second quarter valued at about $126,000. Virginia Retirement Systems ET AL bought a new position in ImmunoGen in the third quarter valued at about $136,000. Finally, SG Americas Securities LLC raised its position in ImmunoGen by 75.7% in the fourth quarter. SG Americas Securities LLC now owns 18,416 shares of the biotechnology company’s stock valued at $118,000 after purchasing an additional 7,937 shares during the last quarter. Hedge funds and other institutional investors own 67.97% of the company’s stock.
ImmunoGen, Inc is a clinical-stage biotechnology company that develops targeted cancer therapeutics using its antibody-drug conjugate (ADC) technology. An ADC with the Company’s technology comprises an antibody that binds to a target found on tumor cells conjugated to one of its anti-cancer agents as a payload to kill the tumor cell once the ADC has bound to its target.
Receive News & Ratings for ImmunoGen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ImmunoGen and related companies with MarketBeat.com's FREE daily email newsletter.